Abbonarsi

Contemporary epidemiology of infective endocarditis in patients with congenital heart disease: A UK prospective study - 05/08/19

Doi : 10.1016/j.ahj.2019.05.014 
TJ Cahill, MRCP DPhil a, 1, PD Jewell, BM BCh b, 1, L Denne c, RC Franklin, MBBS MD d, A Frigiola, MD e, E Orchard, MA MRCP a, BD Prendergast, DM FRCP e,
a Oxford Heart Centre, Oxford University Hospitals, Oxford, UK 
b Imperial College Healthcare NHS Trust, London, UK 
c National Institute for Cardiovascular Outcomes Research, Bart's Health NHS Trust, London, UK 
d Department of Paediatric Cardiology, Royal Brompton Hospital, London, UK 
e Department of Cardiology, St Thomas' Hospital, London, UK 

Reprint requests: Professor B.D. Prendergast DM FRCP, Department of Cardiology, St Thomas' Hospital, London, UKDepartment of Cardiology, St Thomas' HospitalLondonUK

Abstract

Objectives

Infective endocarditis is a life-threatening complication of congenital heart disease (CHD), but there are few studies concerning the contemporary risk profile, preceding invasive procedures and outcomes in this patient population. The aim of this study was to investigate the epidemiology of infective endocarditis (IE) in patients with CHD.

Methods

Cases of IE in children and adults with CHD were prospectively recorded as part of the UK National Institute for Cardiovascular Outcomes Research (NICOR) National Congenital Heart Disease Audit. Patients were entered into the database between April 2008 and March 2016.

Results

Eight hundred episodes of IE were recorded in 736 patients with CHD. Sixty-five patients (9%) were infants (aged <1 year), 235 (32%) were children (aged 1–15 years), and 436 (59%) were adults (aged >15 years). The most common diagnoses were Tetralogy of Fallot (n = 150, 22.8%), ventricular septal defect (n = 129, 19.6%) and bicuspid aortic valve (n = 70, 10.7%). Dental procedures preceded 67 of 635 episodes (11%) of IE, and non-dental invasive procedures preceded 177 of 644 episodes (27.4%). The most common causative organisms were streptococci, accounting for 40% of cases. Overall in-hospital mortality was 6.7%. On multivariable analysis, adverse factors associated with in-hospital mortality were staphylococcal infection and presence of an underlying atrioventricular septal defect.

Conclusions

Infective endocarditis in patients with CHD is an ongoing clinical challenge. In contemporary practice in tertiary congenital centers, 1 of 15 patients do not survive to hospital discharge. Streptococci remain the most common causative organism, and antecedent dental or medical procedures were undertaken in a significant minority in the 3 months before diagnosis. The presence of an atrioventricular septal defect or staphylococcal infection is associated with significantly increased risk of early mortality.

Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : AS, AR, ASD, AVSD, PDA, TGA, TOF, VSD, UVH


Mappa


 Contributions
Thomas Cahill: conceptualization, data curation, writing—original draft preparation, investigation. Paul Jewell: data curation, investigation, writing—original draft preparation. Lin Denne: data curation. Rodney Franklin: conceptualization, writing—review & editing, methodology. Alessandra Frigiola: data curation, writing—review & editing. Elizabeth Orchard: data curation, writing—review & editing. Bernard Prendergast: conceptualization, methodology, writing—original draft preparation, supervision.


© 2019  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 215

P. 70-77 - Settembre 2019 Ritorno al numero
Articolo precedente Articolo precedente
  • The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: A pilot randomized placebo controlled trial of colchicine following acute myocardial infarction
  • Thomas Hennessy, Linda Soh, Mitchell Bowman, Rahul Kurup, Carl Schultz, Sanjay Patel, Graham S. Hillis
| Articolo seguente Articolo seguente
  • Long-term follow-up and safety assessment of angiogenic gene therapy trial VIF-CAD: Transcatheter intramyocardial administration of a bicistronic plasmid expressing VEGF-A165/bFGF cDNA for the treatment of refractory coronary artery disease
  • Krzysztof Kuku?a, Arkadiusz Urbanowicz, Mariusz K?opotowski, Maciej D?browski, Jerzy Pr?gowski, Jacek K?dziela, Zbigniew Chmielak, Adam Witkowski, Witold Ru?y??o

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.